Literature DB >> 15764366

Class I and class II viral fusion protein structures reveal similar principles in membrane fusion.

David J Schibli1, Winfried Weissenhorn.   

Abstract

Recent crystal structures of Flavivirus and Alphavirus fusion proteins (class II) confirm two major principles of protein machineries that mediate the merger of two opposing lipid bilayers. First, the fusion protein can bridge both membranes tethered by two membrane anchors. Second, refolding or domain rearrangement steps lead to the positioning of both anchors into close proximity at the same end of an elongated structure. Although these two steps are in principle sufficient to pull two opposing membranes together and initiate membrane fusion, accumulating evidence suggests that the process requires the concerted action of a number of fusion proteins at and outside the contact sites. This review will focus on the structures of viral class I and class II fusion proteins and their similarities in facilitating membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15764366     DOI: 10.1080/09687860400017784

Source DB:  PubMed          Journal:  Mol Membr Biol        ISSN: 0968-7688            Impact factor:   2.857


  45 in total

1.  Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins.

Authors:  Bruno Eschli; Katharina Quirin; Alexander Wepf; Jacqueline Weber; Rolf Zinkernagel; Hans Hengartner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay.

Authors:  Mariko Kobayashi; Michael C Bennett; Theodore Bercot; Ila R Singh
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Real-time structural investigation of a lipid bilayer during its interaction with melittin using sum frequency generation vibrational spectroscopy.

Authors:  Xiaoyun Chen; Jie Wang; Cornelius B Kristalyn; Zhan Chen
Journal:  Biophys J       Date:  2007-05-04       Impact factor: 4.033

Review 4.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

5.  The presence of a single N-terminal histidine residue enhances the fusogenic properties of a Membranotropic peptide derived from herpes simplex virus type 1 glycoprotein H.

Authors:  Stefania Galdiero; Annarita Falanga; Mariateresa Vitiello; Luca Raiola; Luigi Russo; Carlo Pedone; Carla Isernia; Massimiliano Galdiero
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

6.  Origins of resistance to the HIVgp41 viral entry inhibitor T20.

Authors:  Brian E McGillick; Trent E Balius; Sudipto Mukherjee; Robert C Rizzo
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

7.  Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein.

Authors:  Berend Jan Bosch; John W A Rossen; Willem Bartelink; Stephanie J Zuurveen; Cornelis A M de Haan; Stephane Duquerroy; Charles A B Boucher; Peter J M Rottier
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

8.  Interaction of the most membranotropic region of the HCV E2 envelope glycoprotein with membranes. Biophysical characterization.

Authors:  Ana J Pérez-Berná; Jaime Guillén; Miguel R Moreno; Ana I Gómez-Sánchez; George Pabst; Peter Laggner; José Villalaín
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

9.  Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry.

Authors:  Jeroen Corver; Rene Broer; Puck van Kasteren; Willy Spaan
Journal:  Virol J       Date:  2009-12-24       Impact factor: 4.099

10.  Screening a peptide library by DSC and SAXD: comparison with the biological function of the parent proteins.

Authors:  Ana J Pérez-Berná; George Pabst; Peter Laggner; José Villalaín
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.